» Articles » PMID: 1866474

CCK Stimulates Growth of Six Human Pancreatic Cancer Cell Lines in Serum-free Medium

Overview
Journal Regul Pept
Specialty Biochemistry
Date 1991 Feb 26
PMID 1866474
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The growth responses of six human pancreatic cancer cell lines (SW-1990, PANC-1, MIA PaCa-2, BxPC-3, RWP-2 and CAPAN-2) to cholecystokinin (CCK) were evaluated in serum-free medium (SFM). In each experiment cells were initially plated in media containing fetal calf serum (FCS) grown for 48-72 h, and then washed with saline. Cells were incubated for an additional 72 to 96 h in medium devoid of FCS in the absence (control) or presence of synthetic CCK analogue (Thr4,Nle7)CCK9 (10(-13) to 10(-9) M), or CCK8 (10(-12) to 10(-9) M), or CCK39 (10(-12) to 10(-9) M). Viable cell counts were performed with a hemocytometer. Growth of each cell line was stimulated in the presence of CCK in serum-free medium, although the magnitude of responses differed. The concentrations of (Thr4,Nle7)CCK9 which stimulated the greatest increase in cell counts as compared to controls for each cell line were: SW-1990, 39% (10(-12) M, P less than 0.05); PANC-1, 45% (10(-9) M, P less than 0.005); MIA PaCa-2, 42% (10(-12) M, P less than 0.005); BxPC-3, 32% (10(-13) M, P less than 0.05); RWP-2, 37% (10(-11) M, P less than 0.005). Maximal response to CCK8 occurred at the 10(-9) M dose for each cell line: MIA PaCa-2, 40% (P less than 0.025); PANC-1, 85% (P less than 0.001); RWP-2, 68% (P less than 0.001) and CAPAN-2, 52% (P less than 0.001). The maximal increase in cell count with CCK39 ranged from 44-74% and occurred with either 10(-11) or 10(-10) M. CCK8 in SFM also stimulated cell growth as well as or better than FCS alone in three out of four pancreatic cell lines.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery.

Abraham T, Armold M, McGovern C, Harms J, Darok M, Gigliotti C Biomedicines. 2024; 12(5).

PMID: 38790986 PMC: 11118934. DOI: 10.3390/biomedicines12051024.


Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.

Ruze R, Song J, Yin X, Chen Y, Xu R, Wang C Signal Transduct Target Ther. 2023; 8(1):139.

PMID: 36964133 PMC: 10039087. DOI: 10.1038/s41392-023-01376-w.


Obesity-related gut hormones and cancer: novel insight into the pathophysiology.

Guzzardi M, Pugliese G, Bottiglieri F, Pelosini C, Muscogiuri G, Barrea L Int J Obes (Lond). 2021; 45(9):1886-1898.

PMID: 34088971 DOI: 10.1038/s41366-021-00865-8.


Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.

Osborne N, Sundseth R, Gay M, Cao H, Tucker R, Nadella S Am J Physiol Gastrointest Liver Physiol. 2019; 317(5):G682-G693.

PMID: 31433212 PMC: 6879893. DOI: 10.1152/ajpgi.00145.2019.


Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells.

Kumari S, Chowdhury J, Sikka M, Verma P, Jha P, Mishra A Medchemcomm. 2018; 8(7):1561-1574.

PMID: 30108868 PMC: 6071963. DOI: 10.1039/c7md00171a.